Detalles de la búsqueda
1.
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals.
Front Immunol
; 15: 1394114, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38873610
2.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
NPJ Vaccines
; 8(1): 67, 2023 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37164959
3.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
medRxiv
; 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35169806
4.
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
mBio
; 12(5): e0190821, 2021 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34544278
5.
Protective dose of a recombinant Newcastle disease LaSota-avian influenza virus H5 vaccine against H5N2 highly pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus in broilers with high maternal antibody levels.
Avian Dis
; 54(1 Suppl): 239-41, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20521638
6.
Protection and differentiation of infected from vaccinated animals by an inactivated recombinant Newcastle disease virus/avian influenza H5 vaccine.
Avian Dis
; 54(1 Suppl): 242-5, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20521639
Resultados
1 -
6
de 6
1
Próxima >
>>